Overview
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Eligibility
Inclusion Criteria:
- Adults 18-75 years with clinical diagnosis of gout.
- Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
- Cohort N: Normal renal function.
- Cohort R: Moderate renal impairment.
Exclusion Criteria:
- Clinically significant hepatic impairment.
- History of Allopurinol hypersensitivity.
- Pregnancy or breastfeeding.
